PTGES3

Across TCGA pan-cancer cohorts, PTGES3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTGES3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PTGES3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTGES3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where PTGES3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.603	0.873	<.001	54	view →
LSCC	DFS	Median	All	0.980	0.900	.007	22	view →
LUAD	DFS	Quartile	III,IV	1.000	0.397	.018	14	view →
HNSC	DFS	Tertile	III,IV	0.487	0.707	.027	6	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTGES3–CCRCC (DFS)

Open the CCRCC breakdown →